INTRODUCTION
Phuong HTA et al effect and decreased extracellular fluid (ECF) volume followed by reduction in BP [12, 13] . Recently, we reported that Ang II inhibits the ANP secretion via AT 1 R [14, 15] whereas Ang III [16, 17] and Ang IV [18] stimulate the ANP secretion via AT 2 R and AT 4 R, respectively. Ang-(1-9) [19] , Ang-(1-5) [20] , and Ang-(1-7) [21, 22] also stimulate the ANP secretion via AT 2 R, and Mas receptor, respectively. However, it is not known whether Ang-(4-8) plays a role in the regulation of ANP secretion. Therefore, we investigated the effects of Ang-(4-8) on hemodynamics and ANP secretion compared to Ang II and if so, defined its signaling pathway in rats.
METHODS

Animals
Male Sprague-Dawley (SD) rats, purchased from Daehanbiolink (Eumsung, Korea), were housed in a temperature-controlled room with a 12:12-h light-dark cycle. Animals were provided free access to standard laboratory chow (5L79 Purina rat & mouse 18% chow, Charles River Laboratories Inc., Wilmington, MA) and water. All of experimental protocols conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publication No. 85-23, revised 1996) and were approved by our institution.
Chemicals
The reagents included the following: Ang-(4-8), Ang II, Losartan, PD123319, U73122, edelfosine, 2-amino-ethoxydiphenyl borate (2-APB), and staurosporine (Sigma-Aldrich, St. Louis, MO, USA), LVV-Hemorphin-7 (LVV-H7; Peptron, Daejeon, Korea), and [ 
Preparation of perfused beating rat atria
Isolated perfused beating atria were prepared using a previously described method [23] . In brief, hearts were rapidly excised after decapitation, and left atria were dissected and inserted into cannula, and ligated by a silk. Cannulated atria were kept in an organ chamber perfused with oxygenated HEPES buffer at 37.0°C, and atria were then paced at 1.2 Hz (duration, 0.4 ms; voltage, 30 V). Intra-atrial pressure was recorded using a Power lab (ML-820, ADInstruments Pvt. Ltd, Australia) via a pressure transducer (Statham P23Db, Oxnard, CA, USA), and pulse pressure was obtained from the difference between systolic and diastolic intraatrial pressure. The composition of HEPES buffered saline was as follows (mM): 10 HEPES, 118 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.2 MgSO 4 , 25 NaHCO 3 , 10 glucose, and 0.1% bovine serum albumin (BSA). The pericardial buffered saline, which contained [ 3 H]-inulin for measurement of translocation of extracellular fluid (ECF), was also oxygenated via silicone tube coils inside an organ chamber.
Atria were perfused for 80 min to stabilize ANP secretion and to maintain a steady-state of [ 3 H]-inulin level in the extracellular space. Atrial perfusate was collected at intervals of 2 min at 4°C at the condition paced at 1.2 Hz. The height, internal diameter, and slope of outflow catheter connected to atria were 5 cmH 2 O, 2.0 mm and 70°, respectively. To induce high atrial stretch, the height of outflow catheter was increased from 5 cmH 2 O to 7.5 cmH 2 O by connecting 2.5 cm length catheter after a 10 min control collection period and atrial perfusate was collected for 40 min [24] . The loaded volume to atria during diastole in low-and highstretched conditions was 434 and 736 µl, respectively.
Experimental protocols
Experiments were performed with 10 groups using isolated perfused atria.
Group 1 and 2 were high-stretched atria perfused with either vehicle (n=15) or Ang-(4-8) (0.01 µM, n=10; 0.1 µM, n=10; 1 µM, n=10) [16] . After a 10 min control collection period, the height of outflow catheter was increased from 5 cmH 2 O to 7.5 cmH 2 O and Ang-(4-8) or vehicle was simultaneously perfused for 40 min [24] . Group 3, 4, and 5 were high-stretched atria perfused with Ang- (4) (5) (6) (7) (8) in the presence of AT 1 R, AT 2 R, or AT 4 R antagonist. Atria were perfused with losartan (1 µM, n=10) [14] , PD123319 (1 µM, n=10) [16] , or LVV-H7 (1 µM, n=10) [18] at 10 min before sample collection. After a 10 min control collection period, the height of outflow catheter was increased from 5 cmH 2 O to 7.5 cmH 2 O and Ang-(4-8) (0.1 µM) or vehicle (n=8 for each antagonist) was simultaneously perfused for 40 min [24] . Group 6, 7, 8 , and 9 were high-stretched atria perfused with Ang- (4) (5) (6) (7) (8) in the presence of signaling pathway inhibitors. Atria were perfused with inhibitor for PLC (U73122, 10 µM, n=10; edelfosine, 1 µM, n=10), IP 3 receptor (2APB, 1 µM, n=10), or PKC (staurosporine, 1 µM, n=10) [25] at 10 min before sample collection. After a 10 min control collection period, the height of outflow catheter was increased from 5 cmH 2 O to 7.5 cmH 2 O and Ang-(4-8) (0.1 µM) or vehicle (n=8 for each inhibitor) was simultaneously perfused for 40 min [24] . Group 10 was high-stretched atria perfused with Ang II (0.01, n=8; 0.1 µM, n=8) to compare to the inhibitory effect of Ang-(4-8) (0.01, n=10; 0.1 µM, n=10) on ANP secretion.
In vivo infusion of Ang-(4-8) or Ang II
Experiments were also performed using anesthetized rats to measure changes in hemodynamics by Ang-(4-8). Male SpragueDawley rats, weighing 250~300 g, were anesthetized by intraperitoneal injection of mixture of ketamine and xylazine (9:1, 2 ml/ kg) [16] . Body temperature was maintained at 37°C by a heating pad. After midline incision in the neck, jugular vein and carotid artery were carefully dissected, cannulated with polyethylene tube (PE-50), and secured with ligation. The cannula in jugular vein was connected to a peristaltic pump (Minipuls 2 Gilson, Villiers le Bel, France) for infusion of Ang- (4) (5) (6) (7) (8) or Ang II at a constant rate of 60 µl/min [16] . The cannula in carotid artery was connected to a pressure transducer (Statham P23Db) and mean arterial pressure (MAP) and heart rate (HR) were recorded using a power lab (ML-820, ADInstruments Pvt. Ltd.). After stabilization for 10 min, various doses of Ang-(4-8) (n=5) or Ang II (n=5) were infused for 20 s and measured MAP and HR. The interval between doses was 5 min.
Radioimmunoassay of ANP concentration
The concentration of ANP in perfusates and plasma was measured using a specific RIA, as described previously [26] . The intra-and inter-assay co-efficiency of variation were 6.3% (n=9) and 7.8% (n=11), respectively. The amount of secreted ANP was expressed in ng/min/g of atrial tissue. We previously reported on a two-step sequential mechanism of ANP secretion; first, the stored ANP is released from atrial myocytes into the interstitial space by atrial distension, and, second, the released ANP is secreted into the atrial lumen, concomitant with ECF translocation by atrial contraction [27, 28] . Therefore, the molar concentration of ANP release into the interstitium was calculated as follows:
Because the ANP secreted was found to be the processed ANP, the denominator 3063 indicates the molecular mass of ANP (Da) [28] . 
Measurement of ECF translocation
Statistical analysis
Results are presented as mean±SEM. Statistical significance of the differences was assessed using analysis of variance followed by the Bonferroni multiple comparison test. Student's t test was also used. The critical level of significance was set at p<0.05. Fig. 1 shows the effects of Ang-(4-8) on high stretch-induced atrial contractility and ANP secretion with time. By high atrial stretch, atrial contractility and the secretion of atrial ANP increased significantly and maintained constantly throughout the experiments (Fig. 1A) . When different doses of Ang-(4-8) (0.01 µM, 0.1 µM, and 1 µM) were perfused into atria during high atrial stretch, atrial contractility (Fig. 1Aa ) and ANP secretion (Fig.  1Ab) tended to decrease.
RESULTS
Effects of Ang-(4-8) on high stretch-induced atrial contractility and ANP secretion
To compare quantitatively the effects of Ang-(4-8) on high stretch-induced atrial parameters, data were recalculated by the percent change from the mean of the control period (fraction no. 1 to 5) and the peak period (fraction no. 21 to 25). Application of high atrial stretch increased atrial contractility and ANP secretion by 58.7±4.4% and 66.7±4.4%, respectively. By increasing the doses of Ang-(4-8) to 0.01, 0.1, and 1 µM, high stretch-induced ANP secretion gradually decreased from 66.7±4.4% to 46.3±6.6%, 34.6±4.3%, and 39.1±1.7%, respectively, in a dose-dependent manner (Fig. 1Bb) . Even though the dose of Ang-(4-8) increased up to 10 µM, high stretch-induced ANP secretion was similar to that by 1 µM Ang-(4-8) (data not shown). Atrial pulse pressure Phuong HTA et al was decreased from 58.7±4.4% to 40.4±5.5% by the highest dose of Ang-(4-8) (1 µM) (Fig. 1Ba) .
Effects of Ang-(4-8) on high stretch-induced atrial parameters in the presence of Ang receptor antagonists
To define Ang receptor subtypes related to Ang-(4-8)-induced suppression of ANP secretion, specific receptor antagonist for AT 1 R (losartan, 1 µM), AT 2 R (PD123319, 1 µM) or AT 4 R (LVV-H7, 1 µM) was pretreated 20 min before the administration of Ang-(4-8) or vehicle. We then compared two groups, Ang-(4-8) and vehicle groups in the presence of each antagonist. Losartan, PD123319 or LVV-H7 did not show any significant changes in atrial parameters [14] [15] [16] 22] . Ang-(4-8) (0.1 µM) decreased ECF translocation, ANP secretion and concentration without change in atrial contractility. Pretreatment with losartan thoroughly blocked Ang-(4-8)-induced suppression of ANP secretion and con centration (Figs. 2C and 2D) . However, pretreatment with PD123319 or LVV-H7 did not affect Ang-(4-8)-induced suppression of ANP secretion and concentration (Figs. 2C and 2D) . The decreased ECF translocation by Ang-(4-8) was abolished by the pretreatment with lo sartan and LVV-H7 but not by PD123319 (Fig.  2B) .
Changes in effects Ang-(4-8) on high stretch-induced atrial parameters in the presence of signaling inhibitors
To define the downstream signaling pathway of Ang-(4-8)-induced suppression of ANP secretion through Ang receptor subtypes, several inhibitors such as PLC (U73122, 10 µM ; edelfosine, 1 µM), IP 3 receptor (2APB, 1 µM) or PKC (staurosporine, 1 µM) were perfused 20 min before the administration of Ang-(4-8) or vehicle. We compared two groups, Ang-(4-8) and vehicle groups in the presence of each antagonist. Pretreatment with U73122, edelfosine, 2APB, or staurosporine attenuated Ang-(4-8)-induced suppression of ANP secretion (Fig. 3C ) and ANP concentration (Fig. 3D) . U73122, edelfosine, 2APB, or staurosporine did not show any significant changes in atrial parameters [14] [15] [16] 22] . Phuong (Fig. 4A and 4B ). Both Ang II and Ang-(4-8) inhibited ANP secretion and concentration ( Fig. 4C and 4D) . Even though the effects of Ang-(4-8) and Ang II on the ANP concentration appear to be somewhat different at the concentration of 0.01 µM in Fig. 4D , no statistical differences in ANP secretion and concentration by Ang II and Ang-(4-8) were found. Fig. 5 shows the comparison of hemodynamic changes by Ang-(4-8) and Ang II in anesthetized rats. Different doses of Ang II or Ang-(4-8) were infused intravenously into anaesthetized rats and BP and HR were measured. Ang II 1 nM increased MAP by 30% (Fig. 5A) and decreased HR by 7% (Fig. 5B) . However, Ang-(4-8) 1 µM started to increase MAP. Ang-(4-8) 10 µM increased MAP by 27% and decreased HR by 10%.
Comparison of effects of
HTA et al change in ECF translocation and Ang-(4-8) (0.01 µM) decreased ECF translocation without change in PP
DISCUSSION
The present study shows that Ang-(4-8) suppressed atrial ANP secretion and this effect was attenuated by the pretreatment with AT 1 R antagonist but not with AT 2 R antagonist and AT 4 R antagonist. Ang-(4-8)-induced suppression of ANP secretion was blocked by the pretreatment with inhibitor for PLC, IP 3 receptor, and PKC. Inhibitory effect of ANP secretion by Ang-(4-8) was similar to that by Ang II but the pressure effect of Ang-(4-8) was 10,000 times less potent than Ang II. Therefore, we suggest that Ang-(4-8) suppressed high stretch-induced ANP secretion through AT 1 R and PLC/IP 3 /PKC pathway.
Ang II is metabolized to the truncated forms such as Ang III, Ang IV, Ang-(4-8), Ang-(1-9), Ang-(1-7), and Ang-(1-5), which are found in the circulation with different concentrations. Recently, many studies have been demonstrated that the truncated Angs have different effects on BP, cellular proliferation, and ANP secretion. Ang-(4-8) is found in the circulation but there are a few reports about the biological function of Ang-(4-8) [10, 29] . Different behavioral effects of Ang II and Ang-(4-8) have been reported in rats [29] and Ang-(5-8) has been reported to inhibit GH3 rat pituitary tumor cell proliferation independent of both MAPK p44/42 and MAPK p38 [30] . In the present study, therefore, we investigated the effects of Ang (4-8) on ANP secretion using isolated perfused rat atria. We found that Ang-(4-8) suppressed high stretch-induced ANP secretion without change in atrial contractility from isolated perfused rat atria. Ang II is metabolized to Ang-(2-8) (Ang III), Ang-(3-8) (Ang IV), and Ang-(4-8). However, Ang II inhibits ANP secretion [14] whereas Ang III and Ang IV stimulate ANP secretion in high atrial stretch condition [16] . Therefore, we compared the suppressive effect of Ang-(4-8) on ANP secretion to Ang II. Interestingly, the inhibitory potency of Ang-(4-8) on ANP secretion was similar to that of Ang II. This is the first report showing a potent inhibitory effect of Ang-(4-8) on ANP secretion similar to Ang II.
To define the receptor subtypes involving the Ang-(4-8) effect, atria were pretreated with a specific antagonist of Ang receptor. The pretreatment with AT 1 R antagonist attenuated Ang-(4-8)-induced suppression of ANP secretion but the pretreatment with AT 2 R and AT 4 R antagonist did not. These results suggest that the inhibitory effect of Ang-(4-8) on ANP secretion is mediated via AT 1 R but not via AT 2 R and AT 4 R. It has been reported that the АТ1R activates PLC, leading to an increase of cytosolic Ca 2+ concentration and a stimulation of PKC [31] . Activation of AT 1 R in pancreatic β cells also increases intracellular Ca 2+ concentration by stimulating both extracellular Ca 2+ influx and PLC-IP 3 -sensitive Ca 2+ release from sarcoplasmic reticulum [32] . Therefore, in the present study, we investigated whether Ang-(4-8)-induced suppression of ANP secretion is mediated via AT 1 R and PLC-IP 3 -PKC pathway. Ang-(4-8)-induced suppression of ANP secretion was attenuated by the pretreatment with PLC inhibitor (U73122 and edelfosine). Either the inhibition of PKC (staurosporine) or IP 3 R (2APB) abolished the suppressive effect of Ang-(4-8) on stretchmediated ANP secretion. This indicates IP 3 R-Ca 2+ signaling may be an upstream signal that activates PKC, and further suggests that the Ca 2+ -dependent PKCs among several PKC isoforms may play a role in this signaling pathway. Therefore, we suggest that Ang-(4-8) suppressed high stretch-induced ANP secretion through AT 1 R and PLC/IP 3 /PKC pathway. These data are partly consistent with the reports showing the stimulation of the intrinsic apoptotic pathway by Ang II via AT 1 R/PLC/PKC pathway in cultured cardiac fibroblasts [31] and in pancreatic β cells [32] .
From the above results, the suppressive effect of ANP secretion by Ang-(4-8) was similar to that by Ang II. Finally, we compared the pressor effect of Ang II with Ang-(4-8) in anesthetized normal rats. Both Ang II and Ang-(4-8) increased MAP in a dose-dependent manner. Ang II 1 nM increased MAP by 30% but Ang-(4-8) 10 µM increased MAP by 27%. Ang-(4-8) seems to be 10,000 times less potent in increasing BP than Ang II. Our data are consistent with the previous reports showing that Ang-(4-8) does elicit a minimal pressor action much less than that of Ang IV in human and rats are less responsive to Ang-(4-8) than human [33] . We do not know exactly the reason why the potency of the effects of Ang-(4-8) on ANP secretion and on blood pressure in comparison to those of Ang II shows significant discrepancy. Kono et al [33] have shown the pressor activities of Ang II, Ang III, Ang IV and Ang-(4-8) in human are approximately 100:20:0.2:0.12. Ang III and Ang-(4-8) have 10% [16] and less than 0.1% of the pressor activity of Ang II, respectively. In contrast, Ang III and Ang-(4-8) have 100% of the aldosterone secreting activity [7] and the ANP inhibiting activity of Ang II, respectively. Therefore, N-terminal amino acid of Angs seems to be more important to increase BP. Even though we did not measure the plasma concentration of Ang-(4-8) in normal condition, it has been reported that Ang-(4-8) exists in normal human blood (2.5±1.0 pM or less) [4] . The plasma concentration of Ang-(4-8) may be changed during the activation of RAS in certain pathological conditions [4] , where the role of Ang-(4-8) may be expected.
In conclusion, we suggest that Ang-(4-8) suppressed high stretch-induced ANP secretion through AT 1 R and PLC/IP 3 /PKC pathway. Ang-(4-8) is a biologically active peptide which functions as an inhibition mechanism of ANP secretion rather than an increment of BP compared to Ang II.
